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Shiga toxin, Shiga-like toxin I (SLT-I) and Shiga-like toxin II (SLT-H) are cell-associated cytotoxins that kill
both Vero cells and HeLa cells, whereas Shiga-like toxin II variant (SLT-llv) is an extracellular cytotoxin that
is more cytotoxic for Vero cells than for HeLa cells. The basis for these differences in cytotoxin localization and
host cell specificity were examined in this study. The A and B subunit genes of Shiga toxin and the SLTs were
recombined by two methods so that hybrid toxins would be formed in vivo. Complementation of heterologous
subunits was accomplished by cloning the individual A and B subunit genes of SLT-I, SLT-II, and SLT-llv on
plasmid vectors of different incompatibility groups so that they could be maintained in double transformants
of Escherichia coli. In addition, six operon fusions were constructed so that the A and B subunit genes of Shiga
toxin, SLT-II, and SLT-Hv could be expressed as a single operon. The activities of the hybrid cytotoxins were
assessed in three ways: (i) level of cytotoxicity, (ii) ratio of HeLa to Vero cell cytotoxicity, and (iii) ratio of
extracellular to cell-associated cytotoxicity. Neither the A subunit of Shiga toxin nor SLT-I associated with a
heterologous B subunit to form an active cytotoxin. However, in all other cases the hybrid molecules formed
by subunit complementation or operon fusion were cytotoxic. Furthermore, the cytotoxic specificity and
localization of the hybrid cytotoxins always corresponded to the activities of the native toxin possessing the same
B subunit.

The Shiga-like cytotoxins (SLTs; also called Verotoxins)
have been categorized into two antigenically distinct types.
The first group includes Shiga toxin and SLT-I, which are
neutralized by anti-Shiga toxin and monoclonal antibodies to
the SLT-I B subunit (24, 25, 33). These toxins are now
referred to as Shiga toxin/SLT-I on the basis of the recent
finding that the stx and slt-I nucleotide sequences are essentially identical (13, 33). Indeed, there are only three nucleotide differences between stx and slt-I, which result in an
identical deduced amino acid sequence except at positions
45 of the A subunit (Shiga toxin has a threonine, whereas
SLT-I has a serine at that position). The second group of
SLTs includes SLT-II and SLT-IIv, both of which are
neutralized by polyclonal antisera against SLT-II (21, 27) but
not by anti-Shiga toxin. SLT-IIv is classified as a variant of
SLT-II because it is significantly more cytotoxic for Vero
cells than for HeLa cells (21). SLT-I and SLT-II are produced by enterohemorrhagic Escherichia coli that cause
hemorrhagic colitis and the hemolytic uremic syndrome in
humans (21, 35, 39; S. M. Scotland, H. R. Smith, G. A.
Willshaw, and B. Rowe, Letter, Lancet ii:216, 1983), while
SLT-IIv is produced by E. coli isolated from swine with
edema disease (21).
The mechanisms of action of Shiga toxin, SLT-I, SLT-II,
SLT-IIv, and the plant toxin ricin are the same (6, 7, 31).
These toxins are N-glycosidases that cleave a specific adenine residue from the 28S subunit of eucaryotic rRNA,
which results in the inhibition of protein synthesis. These
bipartite toxins consist of an A subunit, which is responsible
for the enzymatic activity, noncovalently linked to multiple
*

B subunits that are responsible for binding to cellular receptors (4, 26, 28). The eucaryotic receptor to which the B
subunits of Shiga toxin, SLT-I, and SLT-II bind is a galactose-al,4-galactose-containing glycolipid designated Gb3
(12, 16-18, 36). SLT-IIv does not bind to a Gb3 analog,
galactose-al,4-galactose conjugated to bovine serum albumin, which suggests that SLT-IIv may bind a different
cellular receptor than the other members of the Shiga toxin
family do (10, 38).
Individual subunits of SLT-I and SLT-II can assemble to
form fully cytotoxic hybrid molecules in vitro, as recently
demonstrated by Ito et al. (11) with purified A and B subunits
of the toxins. In the study presented here, heterologous
cytotoxins comprised of the individual subunits of Shiga
toxin/SLT-I, SLT-II, and SLT-IIv were created in vivo by
complementation and by operon fusion. The relative importance of the A and B subunits for determining cell specificity
and extracellular localization of holotoxin was assessed.
MATERIALS AND METHODS
Bacterial strains and plasmids. The bacterial strains and
plasmids used in this work are listed in Table 1.
Media, enzymes, biochemicals, and radionuclides. Luria
broth or Luria broth agar (19) was used for routine culturing
of bacteria. Where indicated, media were supplemented with
antibiotics (Sigma Chemical Co., St. Louis, Mo.) at the
following concentrations: ampicillin (50 ,ug/ml), chloramphenicol (50 ,g/ml), kanamycin (50 ,ug/ml), and tetracycline
(12.5 ,g/ml). Agarose for DNA electrophoresis was purchased from International Biotechnologies, Inc. (New Haven, Conn.).
Restriction enzymes were purchased from Boehringer
Mannheim Biochemicals (Indianapolis, Ind.). DNA poly-
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TABLE 1. Bacterial strains, plasmids, and bacteriophages used in this work
Description

Strain or plasmid

Strains
E. coli HB101

F- hsdS20(rB-

mB)

or

Reference

genotypea

recAB3 ara-14 proA2 lacYl galK2

or source

32

rpsL20(Sm`) xyl-5 mtl-l supE44 XE. coli DH5a
E. coli JM109

Plasmids
pBR329
M13 mpl8 and mpl9
pACYC184
pBluescript SK
pBluescribe
pJN25
pNAS10
pNN103
pMJ100

pDLW5
pDLW5.3
pDLW5.104
pMJ153
pMJ330
pDLW5.321
pDW8
pMJ331
pDLW101
pJN26
pDLW102
pDLW103
pDLW104
pDLW105
pFUS1
pFUS2
pFUS3
pFUS4
pFUS5
pFUS6

F' 4i80dlacZ A(lacZYA-argF)U169 recAl endAl hsdRJ7(rK
mK+) supE44 X- thi-I gyrA relAl
endAl gyrA96 thi hsdRJ7 supE44 relAl traD36 A(lac proAB)IF'
proAB lacIqZ M15

32

Tcr, Apr, Cmr; replicon ColEl
Sequencing vectors
Cmr Tcr, replicon P15A
Apr, expression vector
Apr, expression vector
pBR328 with slt-I; Apr
pBR329 with stx; Apr
pBR328 with slt-Il; Apr
pBluescribe with slt-Il; Apr
pBR329 with slt-IIv; Apr
pDLW5 with EcoRI 5' to slt-IIvA
pDLW5 with EcoRI in slt-IIv A
pNAS10 with created EcoRV site; Apr
pMJ100 with created HpaI site; Apr
pDLW5.3 with created HpaI site; Apr
pBR328 with slt-I; mini-Mu in B subunit gene; Kmr, Apr
pBluescribe with slt-II A from pMJ330; Apr
pACYC184 with slt-I A; Cmr
pBR328 with slt-I B; Apr
pACYC184 with slt-II A; Cmr
pBluescript with slt-II B; Apr
pACYC184 with sltll-v A; Tcr
pBluescript with sltll-v B; Apr
4+(slt-IIv A-slt-1I B) in pBR329; Apr
4(slt-II A-slt-IIv B) in pBR329; Apr
4(stx A-slt-II B) in pBR329; Apr
4(slt-II A-stx B) in pBR329; Apr
4i(stx A-slt-IIv B) in pBR329; Apr
4(slt-IIv A-stx B) in pBR329; Apr

3
Boehringer Mannheim
2
Stratagene
Stratagene
22
33
23
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
22
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study

Bethesda Research Laboratories,
Gaithersburg, Md.

a Abbreviations: Tcr, Apr, Cmr, and Kmr, resistance to tetracycline, ampicillin, chloramphenicol, and kanamycin, respectively. stx, Shiga toxin
Shiga-like toxin operon; A, A subunit gene; B, B subunit gene (of stx or slt); operon fusion.

operon;

slt,

4),

merase I (Klenow fragment), calf intestinal alkaline phosphatase, T4 DNA ligase, and DNA kinase were purchased
from Boehringer Mannheim. Sequenase DNA sequencing kit
was purchased from U.S. Biochemicals Corp., Cleveland,
Ohio. The DNA mutagenesis kit was purchased from BioRad Laboratories (Richmond, Calif.).
Radionuclides were purchased either from Dupont, NEN
Research Products (Boston, Mass.) or from Amersham
Corp. (Arlington Heights, Ill.).
Cytotoxicity and neutralization assays. Microcytotoxicity
assays were done on Vero and HeLa cells according to
modifications described previously (20) of the published
methods of Gentry and Dalrymple (9). The amount of toxin
contained in the last 10-fold dilution of the sample in which
greater than or equal to 50% of the HeLa or Vero cells
detached from the plastic, as assessed by A620, was considered to be the 50% cytotoxic dose (CD50).
Toxin neutralization assays with polyclonal anti-SLT-II
and anti-Shiga toxin were done as described previously (24).
Cloning and DNA preparation. Routine cloning and preparation of plasmid DNA procedures were done as described
by Maniatis et al. (19). When appropriate, individual restriction fragments were isolated by electroelution by following
the instructions supplied by the manufacturer of the electroeluter (International Biotechnologies).
Nucleotide sequence analysis. Either the M13 universal

primer (New England BioLabs, Inc., Beverly, Mass.) or
synthetic oligonucleotides prepared with a model 380A DNA
synthesizer (Applied Biosystems Inc., Foster City, Calif.)
were used as primers in the dideoxy-chain terminator
method (1, 29, 30), with a Sequenase kit (U.S. Biochemicals
Corp.), by the method provided by the supplier of the kit.
Oligonucleotide-directed site-specific mutagenesis. The procedure for oligonucleotide-directed site-specific mutagenesis
was modified from the protocol of Zoller and Smith (40).
Single-stranded M13 DNA containing the selected insert was
purified from E. coli CJ236 by using standard procedures
supplied in the kit (Bio-Rad). A synthetic oligonucleotide
(25- to 30-mer) with one or three nucleotide difference(s)
from the wild-type gene was annealed to the uracil-containing, single-stranded DNA template. The second strand
was then synthesized by using DNA polymerase 1 (Klenow
fragment) and deoxynucleoside triphosphates (dATP, dCTP,
dGTP, and TTP; Sigma). The 3' and 5' ends of the newly
synthesized strand were ligated with T4 DNA ligase. The
ligation mixtures were used to transfect E. coli JM109, and
the transfectants were plated for plaque detection by using a
1% Luria broth agar overlay containing approximately 2 x
108 logarithmic-phase E. coli JM109 (32). Single-stranded
phage DNAs were prepared from selected transfectants, and
the nucleotide sequences were determined. Isolates containing the desired mutation were plaque purified and rese-
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FIG. 1. Physical maps of the modified stx, slt-II, and slt-IIv operons cloned in plasmids pMJ153, pMJ330, and pDLW5.321, respectively.
The EcoRI restriction site created by linker insertion and the EcoRV and HpaI sites created by oligonucleotide-directed site-specific
mutagenesis are indicated in italics. Vector DNA is shown by heavy lines, and restriction sites in vector DNA are indicated in bold type. The
location and orientation of the A and B subunit structural genes are shown above the restriction maps. Distances are given in kilobases (kb).

quenced to ensure the fidelity of the mutation. Doublestranded DNA was prepared from the transfectants, and the
desired fragments were used in plasmid construction.
Plasmid construction. As a first step in the construction of
plasmids carrying the individual A or B SLT subunit gene,
unique restriction sites were created in plasmid pDLW5 (38;
contains intact slt-IIv operon) to facilitate subcloning individual restriction fragments. Novel EcoRI restriction sites
were inserted within the RsaI sites of slt-IIv in pDLW5
(Table 1) by using 8-base-pair EcoRI linkers (Pharmacia Fine
Chemicals, Piscataway, N.J.). Plasmid pDLW5 was linearized by partial digestion with RsaI (0.1 U of RsaI per ,ug of
DNA at 37°C for 10 min). The linearized DNA was ligated to
5'-phosphorylated EcoRI linkers, digested to completion
with EcoRI, and subjected to electrophoresis on a 0.7%
preparative agarose gel. Linear plasmid DNA was excised
from the gel, isolated by electroelution, ethanol precipitated,
recircularized by ligation, and transformed into E. coli
HB101. In plasmid pDLW5.3, an EcoRI site was inserted 5'
to the slt-IIv operon, and in pDLW5.104, the EcoRI site was
inserted within the slt-IIv A gene between nucleotide positions 1006 and 1007 (37). The insertion in pDLW5.3 did not
affect the expression of SLT-IIv, as determined by a Vero
cell cytotoxicity assay, whereas the insertion in pDLW5.104
resulted in the complete loss of cytotoxicity (data not
shown). Clones producing high levels of cytotoxicity were
maintained under BL3+EK1 containment (8).
Next, single HpaI or EcoRV restriction sites were created
in the 12 to 15 nucleotide gaps between the A and B subunit
genes of stx, slt-II, and slt-IIv by using oligonucleotidedirected site-specific mutagenesis (Fig. 1; 13, 33, 38). The
specific restriction site created in each operon was selected
for the following reasons: (i) the restriction site did not
naturally exist within the operon; (ii) no more than three
nucleotide changes were required for the creation of any
site; (iii) digestion at all of the created sites generated
blunt-ended DNA fragments which were compatible for the
subsequent construction of operon fusions; and (iv) the
changes did not alter the putative ribosome-binding sequences nor any coding sequences for the B subunit genes.
An EcoRV site was created in the 12 nucleotide gap between
the A and B subunit genes of stx to create pMJ153 (Fig. 1; 33)
by changing the following nucleotides: guanine-1113 to adenine, adenine-1116 to thymine, and adenine-1117 to cy-

tosine. Plasmid pMJ100 was constructed by cloning the
2.3-kilobase (kb) SphI-EcoRI fragment of slt-TI from
pNN103 (23) into the expression vector pBluescribe. To
construct pMJ330, an HpaI site was created in pMJ100 by
changing a guanine to a cytosine in the gap between the A
and B subunit genes of slt-II at position 1204 (13) and in the
slt-IIv operon at position 1212 to construct pDLW5.321 (38;
Fig. 1 and Table 1). These sequence changes did not affect
the expression of the toxin genes, as determined by Vero cell
cytotoxicity assays (data not shown).
The third step in the construction of plasmids for the
complementation studies was to clone the A and B subunit
genes of each cytotoxin into plasmids of different incompatibility groups (Fig. 2). This was done to ensure the stable
cotransformation of a single cell with two plasmids. Plasmids
pDW8, pMJ331, and pDLW5 were used to construct A
subunit subclones of SLT-I, SLT-II, and SLT-IIv, respectively. Plasmid pDW8 (37) carries an operon fusion which
was derived by the insertion of a transposable mini-Mu lac
element into the slt-I B gene of plasmid pJN25 (22). Plasmid
pMJ331, which carries the individual slt-II A subunit gene,
was constructed by cloning the 1.8-kb SphI-HpaI restriction
fragment from pMJ330 (Fig. 1) into the SphI and HincII sites
of the pBluescript vector. The individual A subunit genes of
Shiga toxin/SLT-I, SLT-II, and SLT-IIv were then cloned
into pACYC184, which has a P1SA replicon (2). The B
subunit genes of the SLTs were cloned into either pBR328 or
pBluescript SK, both of which have a ColEl replicon (3). In
previous studies, immunoprecipitation and colony blot assays demonstrated that pJN26 (slt-I B subunit gene in
pBR328) produces SLT-I B subunit (22, 37). The slt-IIv and
slt-1I B subunit genes were cloned into the expression vector
pBluescript SK; hence, the genes were transcribed from a
vector promoter.
Operon fusions. Operon fusions containing the heterologous A and B subunit genes of stx, slt-II, and slt-IIv were
constructed. The A and B subunit genes from plasmids
pMJ153 (stx), pMJ330 (slt-II), and pDLW5.321 (slt-IIv) were
isolated on the appropriate restriction fragments. Each fragment encoding an A subunit was then ligated to a fragment
encoding a different B subunit, and these six operon fusions
were cloned into plasmid vector pBR329. The individual
restriction fragments used for creating the fusions were (Fig.
1): (i) the 1.3-kb SphI-EcoRV (stx A) and 1.4-kb EcoRV-
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FIG. 2. Physical maps of the plasmids carrying the individual A and B subunit genes used in complementation studies. To ensure the stable
cotransformation of a single cell with two plasmids, one carrying an individual A subunit gene and the other carrying an individual B subunit
gene, the A and B subunit genes of each cytotoxin were cloned into plasmid vectors of different incompatibility groups. The restriction sites
which flank the cloned inserts are indicated on each plasmid. Vector DNA is indicated by bold lines (vectors: [A through C], pACYC184; [D],
pBR328; [E and F], pBluescript SK). The source of the cloned insert DNA was: (A), pDW8; (B), pMJ331; (C), pDLW5.3; (D), pJN26
(Newland); (E), pNN103; (F), pDLW5.104. The approximate locations of the subunit genes within the inserts are indicated by arrows. The
abbreviations used are given in Table 1.

EcoRI (stx B) fragments from pMJ153; (ii) the 1.8-kb SphIHpaI (slt-1I A) and 0.5-kb HpaI-EcoRI fragment of pMJ330
(slt-1I B); and, (iii) the 1.7-kb AatII-HpaI (slt-IIv A) and
2.3-kb HpaI-ClaI (slt-IIv B) fragments from pDLW5.321.
The operon fusions, designated pFUS1-6, which are described in Table 1, were confirmed by nucleotide sequence
analysis.
Dot blot analysis. A dot blot assay (modified from the
colony-enzyme-linked immunosorbent assay of Strockbine
et al.; 34) was used to assess whether SLT-I B or SLT-II B
subunit-specific monoclonal antibodies could recognize the
homologous subunit when associated with a heterologous A
subunit. Bacterial cultures (250 ml) were disrupted by sonication. The resulting lysates were then clarified by centrifugation and concentrated by precipitation with ammonium
sulfate (24). The precipitates were dialyzed against phosphate-buffered saline (0.15 M NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, and 1.5 mM KH2PO4, pH 7.6), and the volumes
were brought to 1 ml with phosphate-buffered saline. Portions (5, 10, and 30 ,ul) of the ammonium sulfate-precipitated
samples were spotted on nitrocellulose membranes (Millipore Corp., Bedford, Mass.). Immunochemical staining of
the blots was accomplished as follows: (i) the blots were
blocked with 1% (wt/vol) bovine serum albumin (Sigma) in
Tris-buffered saline (20 mM Tris hydrochloride, 500 mM
NaCl; pH 7.5) for 1 h at room temperature with gentle
agitation; (ii) the blots were incubated for 1 h at room
temperature with monoclonal antibody specific for the SLTII B subunit (5; 1:5,000 dilution of mouse ascitic fluid in
Tris-buffered saline-1% bovine serum albumin), and unbound antibody was removed by five 5-min washes with
0.05% Tween 20 (Sigma) in Tris-buffered saline at room
temperature; (iii) the blots were incubated with an alkaline
phosphatase-linked goat anti-mouse IgG (Stratagene; 1:5,000
dilution in Tris-buffered saline-1% bovine serum albumin),
and the excess antibody was removed as described above;
and (iv) the blots were developed with the substrate (0.3 mg

of nitroblue tetrazolium per ml and 0.15 mg of 5-bromo4-chloro-3-indolyl phosphate per ml in 100 mM Tris hydrochloride, 100 mM NaCl, and 5 mM MgCl2) in the dark for 15
min.
Radioiodination and immunoprecipitation. E. coli transformed with plasmids carrying individual A or B subunit
genes or operon fusions were disrupted by sonication, and
the proteins in the resulting lysates were labeled with 1251 as
previously described (24). The iodinated proteins were immunoprecipitated with monoclonal antibody BC5 to the
SLT-II B subunit (mouse ascitic fluid) as described by
Downes et al. (5). The immunoprecipitates were analyzed on

sodium dodecyl sulfate-15% polyacrylamide gels (14).
RESULTS
Plasmids carrying the individual A and B subunit genes for
Shiga toxin/SLT-I, SLT-TI, and SLT-IIv were constructed
(Fig. 2). To permit the stable cotransformation of host
bacteria, the A subunit genes of stxlsit-I, slt-II, and s1t-IIv
were cloned into the plasmid vector pACYC184, which has
a P1SA replicon (2), and the B subunit genes of the SLTs
were cloned into either plasmid vector pBR328 (3) or expression vector pBluescript SK (Stratagene), both of which have
a ColEl replicon. These vectors also had different antibiotic
resistance determinants so that positive selection for appropriate cotransformants could be maintained.
E. coli HB101 was cotransformed with plasmids carrying
the individual A and B subunit genes from stxlslt-1, slt-II,
and slt-llv in all possible combinations. Sonic lysates and
culture supernatants of the transformants were tested for
cytotoxicity on Vero and HeLa cells to determine the levels
of cell-associated and extracellular cytotoxin. In control
experiments with E. coli HB101 transformed with each of
the individual plasmids encoding one specific A or B subunit,
no cytotoxicity was detected above the levels produced by
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TABLE 2. Complementation studies: cytotoxicity on Vero and
HeLa cells from E. coli HB101 producing hybrid toxins

Cytotoxicity
Vero cells for

Toxin
B
A
subuit
ubunt
subunit
subunit

I
I
I
II
II
II
lIv
lIv

I
II

Ilv

lIv

Ilv
I
II

lIv
I
II

for
Cytotoxicity
HeLa cells

Extra-

%

NDC

7.4

5.6
ND

ND
6.4
6.4
3.4
6.4
6.4
6.4

ND
3.6
5.6
3.6
3.6
5.6
7.6

1
ND
ND
<1
14

Cell

Cell

Extra- ciated
assoaso-cellular" cellular'
ciateda

62
<1
14
94

Extracextulra
c

%
Extracellular

5.6
ND
ND
3.6

1
ND

7.4
ND

ND
-6.4
6.4
ND
5.4
6.4
ND

5.6
ND
3.6
5.6
ND

ND
<1
14
ND
1.4
14
ND

Cell associated, loglo(CD50 per pellet); extracellular, log1o(CD5040 ml of
supernatant).
b % Extracellular (extracellular/[cell associated plus extracellular]) x 100.
c ND, No cytotoxicity detected above the levels produced by E. coli
HB101.
a

E. coli HB101 alone (data not shown). The E. coli HB101
strains containing pairs of plasmids that encoded homologous A and B toxin subunits (Table 2) produced as much or
more cytotoxin than did control HB101 strains containing
the corresponding, intact slt operons on single plasmids
(compare data in Table 2 to pMJ153, pMJ330, and
pDLW5.321 in Table 3). These findings indicated that the A
and B subunits produced by bacteria containing the subclones were biologically active and could associate in vivo to
form functional holotoxins that were distributed between
cell-associated and extracellular compartments in the same
way as the native toxins.
The results of complementation tests with heterologous A
and B subunit genes depended on the specific genes that
were tested. E. coli HB101 cotransformed with pDLW102
and pJN26 (slt-II A and slt-I B) produced approximately 2.5
x 106 CD50 of cytotoxin that was exclusively cell associated
and active on both Vero cells and HeLa cells. E. coli
cotransformed with pDLW102 and pDLW105 (slt-II A and
slt-IIv B) produced only 6.5 x 103 CD50 of cytotoxin that
was predominantly extracellular and was toxic only for Vero
cells. E. coli cotransformed with pDLW104 and pJN26
(slt-IIv A and slt-I B) or pDLW104 and pDLW103 (slt-IIv A
and slt-II B) produced 2.5 x 106 CD50 of cytotoxin that was
active against both Vero and HeLa cells, and in both cases

3747

the toxin was predominantly cell associated. No detectable
cytotoxin was produced by E. coli cotransformed with
pDLW101 and pDLW103 (slt-I A and slt-I1 B) or pDLW101
and pDLW105 (slt-I A and slt-IIv B). Cytotoxins with the B
subunit from SLT-IIv were predominantly extracellular,
whereas toxins with the B subunit from SLT-I or SLT-II
were cell associated (98 and 86%, respectively). The mechanism(s) by which cytotoxins with the B subunit from
SLT-IIv were exported was not determined. These studies
demonstrate that the B subunit determines the cytotoxic
specificity and cellular localization of holotoxin.
Because of the possibility that the copy number of the
individual plasmids expressing A or B subunits might be
different, hybrid cytotoxins produced by operon fusions
were studied to confirm the complementation data. Unlike
the subunit complementation analyses, both the A and B
subunit genes of the fused hybrid operons were transcriptionally regulated by the naturally occurring promoter 5' to
the A subunit gene. Sonic lysates and culture supernatants of
E. coli HB101 transformed with pMJ153 (stx), pMJ330
(slt-II), pDLW5.321 (slt-IIv), or the six operon fusion plasmids were tested on HeLa and Vero cells to determine the
levels of cell-associated and extracellular cytotoxin (Table
3). The cytotoxicity profiles of the hybrid toxins produced by
the operon fusions were similar to those observed in the
complementation studies. E. coli HB101 transformed with
pFUS4 (slt-IIA and stx B) produced approximately 2.5 x 105
total CD50 (cell associated plus extracellular) for Vero and
HeLa cells. E. coli transformed with pFUS2 (slt-II A and
slt-IIv B) produced approximately 6.5 x 104 total CD50 for
Vero cells but was not cytotoxic for HeLa cells. E. coli
transformed with pFUS6 (slt-IIv A and stx B) produced
approximately 2.5 x 105 total CD50 for Vero and HeLa cells.
E. coli transformed with pFUS1 (slt-IIv A and slt-II B)
produced approximately 2.9 x 104 total CD50 for Vero and
HeLa cells. E. coli cotransformed with pFUS3 (stx A and
slt-II B) or pFUS5 (stx A and slt-IIv B) did not produce
detectable levels of cytotoxin. As shown in Table 3, any
cytotoxin containing the B subunit SLT-I or SLT-II was
localized predominantly in the cell-associated fractions,
whereas cytotoxins containing SLT-IIv B subunits were
predominantly extracellular.
Neutralization, dot blot, and immunoprecipitation tests
were done to characterize the immunochemical properties of
the hybrid toxins and to further analyze the reasons for the
lack of complementation between the stxlslt-I A gene and the
B genes of slt-II or slt-IIv. Polyclonal antisera against Shiga

TABLE 3. Operon fusion studies: cytotoxicity on Vero and HeLa cells from E. coli HB101 producing hybrid toxins
Cytotoxicity for HeLa cells
Toxin
Cytotoxicity for Vero cells
Plasmid

pMJ153
pFUS3
pFUS5
pFUS4
pMJ330
pFUS2
pFUS6
pFUS1
pDLW5.321

A subunit

B subunit

Ceda
associateda

Cell

Extracellulara

Shiga
Shiga
Shiga

Shiga

7.4
NDC
ND
5.4
6.4
4.4
5.4
4.4
4.4

5.6
ND
ND
3.6
5.6
4.6
3.6
3.6
4.6

II

lIv

lIv
Shiga
II
lIv
Shiga

IIv

II

II

II
II

IIv

lIv

Extracellular"
xrclua

a Cell associated, loglO(CD50 per pellet); extracellular, loglo(CD5040 ml of supernatant).
b% Extracellular (extracellular/[cell associated plus extracellular]) x 100.
c No cytotoxicity detected above the levels produced by E. coli HB101.

Cell
Extracellular
Extracellular
associated
ascaeExaellr

2

7.4

5.6

2

ND

ND
ND

ND
ND

ND
ND

5.4
5.4

3.6
4.6

2
14

ND

ND

5.4

ND

14

4.4

ND

<1
<!
<1

62

ND

ND

ND

ND
2
14
62
2
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toxin neutralized the hybrid cytotoxins that contained the B
subunit of Shiga toxin/SLT-I, and the hybrid cytotoxins
containing the A or B subunits of SLT-II or SLT-IIv were
neutralized by polyclonal anti-SLT-II serum (data not
shown).
Dot blot immunoassays were done on cell extracts of the
transformants which produced no detectable cytotoxic activity (Shiga/SLT-I A subunit gene with SLT-II or SLT-IIv B
subunit gene) to determine whether the B subunit with its
native epitope was produced. E. coli transformed with
pDLW101 and pDLW103 (slt-I A and slt-II B), pDLW101
and pDLW105 (slt-I A and slt-IIv B), pFUS3 (operon fusion
containing stx A and slt-II B), or pFUS5 (operon fusion
containing stx A and slt-IIv A) produced immunoreactive B
subunits, as assessed by this procedure. Immunoprecipitation studies with these strains demonstrated that the A
subunit of Shiga toxin/SLT-I assembled with the heterologous B subunit of SLT-II or SLT-IIv, even though hybrid
holotoxins containing these subunits were not cytotoxic.
Polypeptides corresponding in molecular weights to both the
processed Shiga toxin/SLT-I A subunit (Mr, 32,000) and the
processed SLT-II or SLT-IIv B subunit (Mr, 7,000) were
immunoprecipitated by monoclonal antibodies specific either for the SLT-I A or the SLT-II B subunit (results not
shown). It should be noted that low-level cytotoxin(s) produced by some wild-type E. coli strains cannot be detected
by either dot blot immunoassays or immunoprecipitation.
To test the possibility that some active toxin was formed
but at levels below detection with our standard assays, sonic
lysates of E. coli transformed with pDLW101 and pDLW103
(slt-I A and slt-II B), pDLW101 and pDLW105 (slt-I A and
slt-IIv B), pFUS3 (operon fusion containing stx A and slt-TI
B), or pFUS5 (operon fusion containing stx A and slt-lIv A)
were further concentrated and tested. When these strains
were concentrated 250-fold by ammonium sulfate precipitation, low levels of cytotoxin were detected (results not
shown). When lysates of the E. coli host strain alone were
similarly concentrated, no cytotoxic activity was detected.
Therefore, the Shiga toxin/SLT-I A subunit and SLT-IIB
and SLT-IIv B subunit can assemble and form active hybrid
toxins, but the cytotoxic activity associated with the E. coli
producing the hybrid toxins was greatly reduced compared
with homologous toxins.
DISCUSSION

The B subunits of Shiga toxin/SLT-I and SLT-II bind to a
eucaryotic cell receptor Gb3 (12, 16-18, 36). However,
SLT-IIv does not bind to an analog of Gb3 in an enzymelinked immunosorbent assay (38), and, unlike Shiga toxin/
SLT-I and SLT-II, SLT-IIv kills Vero but not HeLa cells
(21). The results of this study demonstrated that the different
cell specificity of SLT-IIv compared with Shiga toxin/SLT-I
and SLT-I1 is dictated by the SLT-IIv B subunit. Regardless
of the source of the A subunit, hybrid toxins composed of
the Shiga toxin/SLT-I B or SLT-II B subunit were equally
cytotoxic for both Vero and HeLa cells. In contrast, hybrid
cytotoxins composed of any A subunit and the SLT-IIv B
subunit had the same cytotoxicity profile as SLT-IIv holotoxin, i.e., they killed Vero cells with no detectable activity
on HeLa cells.
Previous studies with E. coli strains lysogenic for SLT-I or

SLT-TI-converting coliphage demonstrated that SLT-1 was
almost completely cell associated, whereas SLT-11 was more
equally distributed between the cell-associated and extracel-
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lular fractions (35). In E. coli producing SLT-IIv, most of the
cytotoxin was localized to the extracellular milieu in E. coli
K12 transformed with a plasmid encoding SLT-IIv (see
pDLW5.321 in Table 3). With hybrid toxins, those that
contained the Shiga toxin/SLT-I B subunit were almost
exclusively cell associated (90%), while those hybrid toxins
that contained the SLT-II B subunit were predominantly cell
associated (86%). In contrast, hybrid cytotoxins that contained the SLT-IIv B subunit were predominantly extracellular (62%). Therefore, as with cell specificity, localization of
the cytotoxins in E. coli is dictated by the source of the B
subunit.
All of the hybrid cytotoxins were neutralized by polyclonal antisera specific for either Shiga toxin/SLT-1 or SLTIT. This observation is in contrast to a recent study by Ito et
al. (11), who found that hybrid cytotoxins containing SLT-1
and SLT-II components were not neutralized by polyclonal
antisera. One explanation for this difference in neutralization
results is that our antisera were raised against native holotoxin, whereas the antitoxins used by Ito et al. were raised
against formalin-treated SLT-I or SLT-II. Perhaps the
epitopes exposed in the hybrid toxins are better recognized
by antisera to native toxin than by antisera raised against the
formalin-treated toxin.
Ito et al. (11) also detected a hybrid toxin composed of the
SLT-I A and SLT-II B subunits with cytotoxic activity
similar to toxin composed of homologous subunits. We were
able to detect association of the Shiga toxin/SLT-1 A subunit
with heterologous SLT-II or SLT-Ilv B subunits in vivo, but
such hybrid molecules were several orders of magnitude less
toxic than Shiga toxin/SLT-1. It is not clear why the specific
toxicity of the SLT-1 A and SLT-11 B molecule formed in
vitro was significantly greater than that of hybrids formed in
vivo in our experiments.
Some inconsistencies were apparent when levels of cytotoxicity were compared between homologous toxins formed
by subunit complementation and operon fusions. For example, the total CD50 produced by transformants of the parental
control plasmids was sometimes higher than transformants
of the hybrid plasmids (e.g., compare pMJ330 to pFUS2 in
Table 3). The reasons for these variations in levels of
cytotoxicity are not clear but may reflect the way in which
the active molecules are assembled. Also, the total cytotoxicity of hybrid toxin produced by subunit complementation
was sometimes different than the levels produced by operon
fusions which combined the same A and B subunits (i.e.,
compare the CD50 of the hybrid toxin composed of SLT-1Iv
A/SLT-II B subunit produced by complementation [Table 2]
to pFUS1 [SLT-Ilv A/SLT-11 B; Table 3]). Explanations for
the production of hybrid toxins with elevated cytotoxicity
compared with the production of native toxins include a gene
dosage effect (e.g., higher plasmid copy number carrying a
subunit gene or hybrid operon) or the enhanced transcription
of a subunit gene or hybrid operon from an extragenic vector
promoter.
In summary, we used subunit complementation and operon fusions to create hybrid cytotoxins. We found that B
subunit dictated the cytotoxic specificity and localization of
the toxin within the bacterial cell. Once these hybrid toxins
are purified, the levels and specific activities of these cytotoxins will be analyzed. We will then be able to assess
whether the levels of cytotoxicity (i.e., moderate or high)
can be attributed to a specific subunit.
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